Drug recall: Carboplatin Injection, 10 mg/mL, a) 5 mL multi-dose vials (NDC 61703-339-18) (NDC 61703-360-18, NOVAPLUS), b) 45 mL mult

FDA enforcement event 62463 · Class III · initiated 2 Jul 2012 · status Terminated · terminated 24 Jul 2017

DrugVoluntary: Firm initiated1 product recordLake Forest, IL

Hospira Inc. (Lake Forest, IL) initiated this drug recall on 2 Jul 2012; FDA lists 1 product record under event 62463, classified Class III.

FDA defines Class III as a situation in which use of or exposure to a violative product is not likely to cause adverse health consequences. 28% of the 209 drug enforcement events initiated in 2012 carry the same class.

Status: Terminated, terminated 24 Jul 2017. Initiation: voluntary: firm initiated. Hospira Inc. has 151 enforcement events on this register, with a median of 1 product record per event.

Recall classification reflects the relative degree of health hazard. Text in quotation marks is FDA's. openFDA export dated 28 Sep 2026.

Recalling firm

Hospira Inc., Lake Forest, IL.

Reason for recall

"Failed PH specification: The lots of Carboplatin Injection were manufactured from Carboplatin API lots which trended out of specification low pH."

Distribution

"Nationwide and Puerto Rico"

Product records

Recall number	Product	Quantity	Class	Status	Report date
D-1648-2012	Carboplatin Injection, 10 mg/mL, a) 5 mL multi-dose vials (NDC 61703-339-18) (NDC 61703-360-18, NOVAPLUS), b) 45 mL multi-dose vials (NDC 61703-339-50) (NDC 61703-360-50 NOVAPLUS), Rx only, Hospira, Inc., Lake Forest, IL 60045, Product of Australia	77,542 vials	Class III	Terminated	22 Aug 2012

Context

28%of 2012 drug events are Class III209 events that year

1product record in this eventfirm median: 1

151events on this register for the firm

Other enforcement events for Hospira Inc.

Initiated	Product (first record)	Type	Class	Records
21 Apr 2017	Infant 25% DEXTROSE Injection, USP, 2.5 g (250 mg/mL), 10 mL Unit of Use Single-dose Syringe per carton, Rx only, Hospir	Drug	Class I	1
1 Nov 2016	Fentanyl Citrate Injection, USP, 100 mcg Fentanyl/ 2mL, Single Dose, 50 mcg/mL, Rx only, Hospira, Inc., Lake Forest IL 6	Drug	Class II	1
15 Aug 2016	DOBUTamine Injection, USP 250 mg/20 mL, 20 mL Vial, For IV Use Only, Must be Diluted Prior to Use, (12.5 mg per mL), Rx	Drug	Class II	1
29 Jun 2016	5% Lidocaine HCL and 7.5% Dextrose Injection, USP, 2 mL Single-dose ampule, 5 count box, Rx Only, For Spinal Anesthesia	Drug	Class III	1
23 Jun 2016	Diazepam Injection USP 10mg/2mL (5 mg/mL, 2 mL), Rx only, Hospira Inc. Lake Forest, IL 60045, NDC 0409-1273-32	Drug	Class II	1
6 May 2016	Vancomycin Hydrochloride for Injection, USP, 10 g, 100 mL vial, Rx only, Hospira, Lake Forest, IL, NDC 0409-6510-01	Drug	Class II	1
25 Mar 2016	The Plum 360 is a large volume infuser capable of delivering fluids for a variety of therapies such as parenteral, enter	Device	Class II	2
23 Mar 2016	Magnesium Sulfate Inj., USP 50%, 10 g/20 mL (0.5 g/mL), (4 mEq Magnesium/mL, 20 mL Single-dose vial, packaged in 25 vial	Drug	Class III	1
23 Mar 2016	Magnesium Sulfate Inj., USP 50%, 10 g/20 mL (0.5 g/mL), (4 mEq Magnesium/mL, 20 mL Single-dose vial, packaged in 25 vial	Drug	Class I	1
18 Mar 2016	8.4% Sodium Bicarbonate Injection, USP 50mEq (1mEq/mL), 4.2 grams (84 mg/mL), 50 mL, Rx only, Hospira Inc, Lake Forest,	Drug	Class I	1

All 151 events for Hospira Inc.

Questions and answers

Why was this drug recalled?

FDA's record gives the reason for recall as: "Failed PH specification: The lots of Carboplatin Injection were manufactured from Carboplatin API lots which trended out of specification low pH."

What does Class III mean?

FDA classifies recalls by relative degree of health hazard. Class III is a situation in which use of or exposure to a violative product is not likely to cause adverse health consequences.

Where was the product distributed?

FDA's distribution pattern field reads: "Nationwide and Puerto Rico"

Is the recall still ongoing?

FDA lists the status as Terminated; the termination date is 24 Jul 2017. "Terminated" means FDA has determined that all reasonable efforts to remove or correct the product have been made.

Where does this data come from?

openFDA enforcement reports (food, drug and device), CC0, export dated 28 Sep 2026. Text in quotation marks is FDA's. The FDA enforcement report linked above is authoritative.

Provenance

Source: openFDA drug enforcement reports (CC0), export dated 28 Sep 2026; records grouped by FDA event number. The class shown for the event is the most severe class among its records. Errors in processing are corrected at the next build; see corrections.